Loading…
CIK 0001633313 • 7 13F filings • May 15, 2025 – Aug 14, 2026
Import this data to Google Sheets with:
=jivedata("avoro-capital-advisors-llc","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| ALKERMES PLC | Common | $39.2M | 0.4%Prev: 0.9% | 1,400,000 SH | Decreased-840,000 SH |
| APELLIS PHARMACEUTICALS INC | Common | $307.0M | 3.0% | 12,222,222 SH | New |
| APOGEE THERAPEUTICS INC | Common | $37.7M | 0.4% | 500,000 SH | New |
| ARGENX SE | Sponsored ADR | $832.5M | 8.2%Prev: 9.4% | 990,000 SH | Increased |
| ARROWHEAD PHARMACEUTICALS INC | Common | $705.4M | 6.9% | 10,625,000 SH | New |
| ASCENDIS PHARMA | Sponsored ADR | $1.09B | 10.7%Prev: 13.1% | 5,161,111 SH | Increased+51,111 SH |
| AVIDITY BIOSCIENCES INC | Common | $393.5M | 3.9%Prev: 4.3% | 5,455,000 SH | Increased-2,190,000 SH |
| CELCUITY INC | Common | $310.3M | 3.0% | 3,111,111 SH | New |
| CENTESSA PHARMACEUTICALS PLC | SPONSORED ADS | $364.0M | 3.6% | 14,555,555 SH | New |
| GH RESEARCH PLC | ORDINARY SHARES | $22.9M | 0.2% | 1,800,000 SH | New |
| INCYTE CORP | Common | $13.3M | 0.1% | 135,000 SH | New |
| KRYSTAL BIOTECH INC | Common | $712.2M | 7.0%Prev: 6.3% | 2,888,888 SH | Increased+111,111 SH |
| KYMERA THERAPEUTICS INC | Common | $581.6M | 5.7%Prev: 4.6% | 7,474,747 SH | Increased+1,124,747 SH |
| LEXEO THERAPEUTICS INC | Common | $32.8M | 0.3% | 3,300,000 SH | New |
| MADRIGAL PHARMACEUTICALS INC | Common | $1.05B | 10.3%Prev: 10.9% | 1,807,500 SH | Increased-25,500 SH |
| MANNKIND CORP | Common | $25.2M | 0.2%Prev: 0.3% | 4,444,444 SH | Increased-24,433 SH |
| MIND MEDICINE (MINDMED) INC | Common | $67.0M | 0.7% | 5,000,000 SH | New |
| OCULAR THERAPEUTIX INC | Common | $130.8M | 1.3%Prev: 1.5% | 10,777,777 SH | Increased+527,777 SH |
| ORUKA THERAPEUTICS INC | Common | $40.4M | 0.4%Prev: 0.3% | 1,333,340 SH | Increased |
| PTC THERAPEUTICS INC | Common | $52.0M | 0.5% | 685,000 SH | New |
| REVOLUTION MEDICINES INC | Common | $172.8M | 1.7% | 2,170,000 SH | New |
| SEPTERNA INC | Common | $37.3M | 0.4%Prev: 0.3% | 1,337,500 SH | Increased |
| SOLENO THERAPEUTICS INC | Common | $134.3M | 1.3%Prev: 2.3% | 2,900,000 SH | Decreased+322,223 SH |
| SPDR SERIES TRUST - S&P BIOTECH | ETF | $256.1M | 2.5% | 2,100,000 SH | New |
| STRUCTURE THERAPEUTICS INC | SPONSORED ADS | $455.9M | 4.5% | 6,555,555 SH | New |
| TAYSHA GENE THERAPIES INC | Common | $119.3M | 1.2%Prev: 0.9% | 21,700,000 SH | Increased |
| TERNS PHARMACEUTICALS INC | Common | $175.7M | 1.7% | 4,350,000 SH | New |
| UNIQURE NV | Common | $147.2M | 1.4%Prev: 3.4% | 6,150,000 SH | Decreased+1,705,556 SH |
| UNITED THERAPEUTICS CORP | Common | $1.27B | 12.5%Prev: 11.0% | 2,606,060 SH | Increased+383,838 SH |
| VERA THERAPEUTICS INC | Common | $298.2M | 2.9%Prev: 2.3% | 5,888,888 SH | Increased-321,112 SH |
| VIRIDIAN THERAPEUTICS INC | Common | $46.7M | 0.5% | 1,500,000 SH | New |
| WHITEHAWK THERAPEUTICS INC | Common | $6.9M | 0.1%Prev: 0.1% | 2,849,402 SH | Increased |
| XENON PHARMACEUTICALS INC | Common | $243.1M | 2.4%Prev: 2.8% | 5,424,444 SH | Increased+24,444 SH |
| 13F-HR |
| 0001104659-26-096427 |
| $11.14B |
| View |
| Aug 14, 2025 | Q2 2025 | 13F-HR | 0001104659-25-078127 | $5.71B | View |
| May 15, 2026 | Q1 2026 | 13F-HR | 0001104659-26-061754 | $10.16B | View |
| May 15, 2025 | Q1 2025 | 13F-HR | 0001104659-25-048904 | $6.41B | View |